

**hVIVO plc**  
("hVIVO" or the "Company")

**hVIVO to present at the upcoming 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain**

**London, UK - 27 September 2019: hVIVO plc (AIM: HVO)**, an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics today announces it will be presenting at the European Respiratory Society Congress being held on September 28 - October 2, 2019 at the IFEMA, Feria de Madrid, Madrid, Spain.

The first presentation will evaluate the use of lower respiratory symptoms as a key endpoint to be used in trials along with the relationships between the endpoint and clinical markers such as lung function and asthma control. The second presentation will focus on the patterns of the immune response to a viral exacerbation in asthmatics and the timing profile of white blood cells as well as nasal and blood immune biomarkers. These presentations highlight the utility of the hVIVO viral challenge model as well as help inform trial design and endpoint selection.

**Andrew Catchpole, Director, Clinical Science, commented;** "We are delighted that our abstracts have been accepted for presentation at the prestigious ERS International Congress. The data summarised in the posters is encouraging and supports our belief that the challenge model is not only helpful as a proof-of-concept for the effectiveness of agents directed at the viruses, but also as proof-of-mechanism for novel products in diseases where respiratory viruses are known to induce exacerbations."

*Poster discussion presentation details:*

**Title: A key endpoint in viral challenge models of asthma exacerbations Poster**

**Authors:** Michael. A. Ghebre, Alan S. Bell, Alex J. Mann

**Date & Time:** 29.09.2019 at 08:30 CEST

**Session Category:** Airway Physiology 08:30-10:30

**Presenter:** Alan S. Bell, Director of Translational Operations

**Location:** 6D

**Conference Reference Number:** 347

*Oral presentation details:*

**Title: Temporal relationships of cytokines, chemokines and cellular biomarkers during Human Rhinovirus (HRV) infection in asthmatics**

**Authors:** Alex J Mann, Michael A Ghebre, Alan S Bell

**Date & Time:** 01.10.2019 at 10:15 CEST

**Session Category:** Blood Eosinophils and More in Airway Diseases 08:30-10:30

**Presenter:** Alan S. Bell, Director of Translational Operations

**Location:** 8A

**Conference Reference Number:** 3564

RNS REACH

A copy of the presentation materials will be made available here: <https://hvivo.com/news-media/scientific-papers/>

**For further information please contact:**

**hVIVO plc**

Fleur Wood (EVP, Investor Relations & Communications)

+44 207 756 1300

**FTI Consulting**

Simon Conway / Victoria Foster Mitchell

+44 203 727 1000

**Notes to Editors:**

hVIVO is an industry leading clinical development services business supporting product development for customers developing antivirals, vaccines and respiratory therapeutics. Leveraging human disease models in human rhinovirus (HRV), RSV, Influenza (Flu) Asthma and chronic obstructive pulmonary disease (COPD), the hVIVO platform illuminates the entire disease cycle in people from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted 56 clinical studies and inoculated over 2900 volunteers.

**Forward-looking statements**

*This announcement includes statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms anticipates, believes, estimates, expects, intends, may, plans, projects, should or will, or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. Any forward-looking statements in this announcement reflect the Group's (or, as the case may be, the hVIVO directors') current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's operations, results of operations and growth strategy. Investors should specifically consider the factors identified in this announcement which could cause actual results to differ before making an investment decision.*